Skip to content
ContentLora

    Tip: press / anywhere to search.

    technology

    Enzymatic DNA synthesis

    Also known as EDS, enzymatic oligo synthesis

    Enzymatic DNA synthesis writes DNA with enzymes in water rather than with the long-established phosphoramidite chemistry, and its vendors market it on length and on benchtop convenience.[1][2] As of October 2026 Ansa Biotechnologies sells clonal constructs up to 50 kilobases and DNA Script has an ARPA-H award of up to $26 million with GE HealthCare for cell-free DNA bioproduction.[2][3]

    Editor reviewedUpdated Synthetic biologyLife sciencesScience
    Key facts

    What it is

    Enzymatic DNA synthesis builds a DNA strand using a template-independent polymerase under mild, aqueous conditions, in place of the organic chemistry cycle that has dominated oligonucleotide manufacture for decades. The practical selling points are length, because less strand damage accumulates per cycle, and deployability, because the chemistry is benign enough for a bench instrument.[1][4]

    Length and price, as marketed

    Ansa Biotechnologies announced in October 2025 that it offered clonal DNA constructs as long as 50 kilobases, roughly 100 times the length of its first product, and said industry-standard approaches generally cannot produce constructs beyond about 10 kilobases.[2][4] Pricing was advertised from about 28 cents per base pair with turnaround under 25 business days.[5] These are company statements rather than independent benchmarks, and should be treated as claims about a product line rather than a measured comparison of chemistries.

    Benchtop and distributed synthesis

    The second commercial pattern is decentralisation. DNA Script’s SYNTAX system is a benchtop printer that produces custom oligonucleotides on site in hours instead of days.[1] The company extended distribution to Latin America and East Asia in March 2026 and to India in July 2026, which widens the number of jurisdictions in which synthesis happens outside a central provider.[6] That matters for order screening, because the 2024 US framework explicitly covers benchtop devices as well as providers.[7]

    Where it is heading

    In August 2026 DNA Script said it and GE HealthCare had been awarded up to $26 million by ARPA-H to advance cell-free DNA bioproduction, targeting faster, distributed DNA manufacturing for next-generation therapies.[3] That points at the likely near-term market: not competing on the cheapest gene, but on making clinical-grade DNA near the point of use.

    Conventional array-based synthesis is not standing still. Twist Bioscience grew its DNA synthesis and protein revenue to $56.6 million in the quarter to June 2026 from $40.8 million a year earlier, and shipped about 369,000 genes.[8][9] Enzymatic providers currently win on construct length and on-site production rather than on unit volume.

    How much DNA the new methods need

    Demand for long constructs is being set by what design methods now attempt. Shotgun Genetic Engineering, published in Nature Biotechnology on 6 October 2026, screens millions of mammalian pathway combinations by delivering many barcoded small constructs instead of one large one, and the pathways that worked required 23 to 52 kilobases of synthetic DNA integrated per cell.[10][11][12] That range sits above the roughly 10-kilobase practical ceiling vendors ascribe to conventional routes and inside the 50-kilobase clonal products enzymatic providers now advertise.[4][2]

    Distribution is widening in parallel. DNA Script added distributors for its benchtop platform in Latin America, Japan and South Korea in March 2026 and in India in July 2026, which is the on-site end of the same demand: oligonucleotides made in a few hours in the laboratory rather than shipped from a synthesis hub.[6][1]

    What is not yet established

    There is no public, independent benchmark comparing enzymatic and conventional synthesis on error rate, yield and cost at matched lengths; the available length and price figures are vendor statements.[2][5][4] Nor is throughput public: how many long constructs are delivered per quarter is not disclosed in the way gene counts are by array-based providers.[9]

    Why length matters

    Longer error-free constructs reduce the number of assembly steps needed for pathways and chromosomes. Genome-scale projects still synthesise in fragments and recombine them, as the four-megabase Syn57 Escherichia coli genome did, and they still require debugging afterwards.[13][14] Any shift of the practical synthesis limit upwards removes a layer of that work.

    Questions readers ask

    How is enzymatic synthesis different from standard DNA synthesis?

    It extends strands using an enzyme in water instead of the organic phosphoramidite cycle, which vendors say allows longer products; Ansa says conventional approaches generally cannot exceed about 10 kilobases.[4][2]

    How long can enzymatically made DNA be?

    Ansa Biotechnologies announced commercial clonal constructs up to 50 kilobases in October 2025, about 100 times the length of its first product.[2]

    Can a lab make its own DNA in house?

    Yes, for short DNA. DNA Script's SYNTAX is a benchtop printer that makes custom oligonucleotides on site in hours rather than days.[1]

    Is enzymatic synthesis commercially established?

    Partly. It is sold as a service and as benchtop hardware, and in August 2026 ARPA-H awarded up to $26 million to DNA Script and GE HealthCare for cell-free DNA bioproduction.[3][6]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      DNA Script's SYNTAX system is a benchtop enzymatic DNA printer that produces custom oligonucleotides on site in hours rather than days. reportedas of 2026-10-10

    2. [2]

      Ansa Biotechnologies announced commercial availability of clonal DNA constructs up to 50 kilobases made on its enzymatic DNA synthesis platform, roughly 100 times longer than its first product. reportedas of 2025-10-01

    3. [3]

      On 4 August 2026 DNA Script said it and GE HealthCare had been awarded up to $26 million by ARPA-H to advance cell-free DNA bioproduction under the FLASH programme. confirmedas of 2026-08-04

    4. [4]

      Ansa Biotechnologies says industry-standard DNA synthesis approaches generally cannot produce constructs longer than about 10 kilobases. reportedas of 2025-10-01

    5. [5]

      Ansa Biotechnologies listed its long clonal DNA from as little as 28 cents per base pair with turnaround under 25 business days. reportedas of 2025-10-01

    6. [6]

      DNA Script expanded distribution of on-demand DNA synthesis to Latin America and East Asia in March 2026 and to India in July 2026. confirmedas of 2026-07-16

    7. [7]

      The 2024 framework makes it a condition of US federal life-sciences research funding that synthetic nucleic acids, and benchtop devices that can make them, are bought only from providers and manufacturers that comply with the framework. confirmedas of 2026-10-10

    8. [8]

      Twist Bioscience's DNA Synthesis and Protein Solutions revenue reached $56.6 million in the third quarter of fiscal 2026, up from $40.8 million a year earlier. confirmedas of 2026-08-05

    9. [9]

      Twist Bioscience shipped about 369,000 synthetic genes in the third quarter of fiscal 2026, against about 237,000 in the same quarter of fiscal 2025. confirmedas of 2026-08-05

    10. [10]

      Nature Biotechnology published "Highly multiplexed mammalian metabolic engineering with a shotgun approach" on 6 October 2026. confirmedas of 2026-10-06

    11. [11]

      Shotgun Genetic Engineering delivers many barcoded small DNA constructs into mammalian cells rather than one large construct, so each cell carries a different synthetic pathway and functional combinations are identified by sequencing barcodes from cells with the wanted phenotype. confirmedas of 2025-07-08

    12. [12]

      The shotgun engineering authors screened millions of pathway combinations in CHO and Jurkat cells, reaching near-wild-type growth in valine-free medium and isoleucine prototrophy in CHO cells, with successful solutions requiring 23 to 52 kilobases of synthetic DNA. confirmedas of 2025-07-08

    13. [13]

      Syn57 is an Escherichia coli strain whose 4-megabase genome was built by total synthesis with more than 101,000 codon changes, giving it a 57-codon genetic code; the work was published in Science in 2025. confirmedas of 2025-08-01

    14. [14]

      The Sc2.0 team used a CRISPR-based debugging protocol, D-BUGS, to locate and correct design errors in synthetic chromosomes that impaired yeast growth. confirmedas of 2025-01-22

    15. [15]

      Sc2.0 is an international project to build the first synthetic eukaryotic genome, a redesigned version of the Saccharomyces cerevisiae genome plus a new-to-nature tRNA neochromosome. confirmedas of 2025-01-22

    Revision history (2)
    1. Page created.
    2. Refresh: re-sourced the SYNTAX description and distribution claims to DNA Script press releases, and added the ARPA-H FLASH award and the DNA length demands of 2026 pathway engineering.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Enzymatic DNA synthesis." ContentLora, updated Oct 10, 2026. https://contentlora.com/wiki/enzymatic-dna-synthesis

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    Connections
    Synthetic yeast gen… Used to buildTwist Bioscience Competes withCell-free protein s… Supplies
    ☰ Contents